In a 64-year-old man, how should testosterone levels be evaluated and managed?

Testosterone Evaluation and Management in a 64-Year-Old Man

In a 64-year-old man, diagnose testosterone deficiency only when total testosterone is below 300 ng/dL on two separate early morning measurements AND the patient has specific symptoms (reduced libido, erectile dysfunction, fatigue, reduced muscle mass, or osteoporosis), then offer testosterone therapy targeting mid-normal range levels (450-600 ng/dL) with mandatory monitoring at 3-6 months and annually thereafter. 1, 2, 1

Diagnostic Approach

Initial Testing Requirements

• Measure total testosterone on two separate occasions, both in early morning (before 10 AM), using the same laboratory and methodology 1
• Use 300 ng/dL as the diagnostic threshold for low testosterone 1
• For men 20-44 years old, age-specific cutoffs are higher (350-575 ng/dL depending on age), but the 300 ng/dL threshold remains appropriate for a 64-year-old 3

Required Clinical Symptoms

Testosterone deficiency requires BOTH low levels AND symptoms. Look specifically for:

• Sexual symptoms: reduced libido, erectile dysfunction, decreased spontaneous erections
• Physical symptoms: reduced muscle mass and strength, increased body fat, osteoporosis/low-trauma fractures, unexplained anemia
• Psychological symptoms: fatigue, reduced energy, depression, poor concentration 1, 2, 1

Critical caveat: Do NOT use screening questionnaires to diagnose testosterone deficiency—they lack adequate sensitivity and specificity 1

Additional Workup

• Measure LH levels to distinguish primary (testicular) from secondary (hypothalamic-pituitary) hypogonadism 1
• Check hematocrit, PSA, and perform digital rectal exam before treatment 2
• Consider measuring free testosterone if total testosterone is borderline (200-400 ng/dL) or if conditions affecting SHBG exist (obesity, diabetes, thyroid disorders) 2

Treatment Decision Algorithm

Absolute Contraindications to Testosterone Therapy

Do NOT treat if patient has:

• Breast or prostate cancer
• PSA >4.0 ng/mL without urological evaluation
• Hematocrit >50% (>48% per most recent guidelines) 2
• Severe heart failure (Class III-IV)
• Untreated severe obstructive sleep apnea
• Severe lower urinary tract symptoms (AUA/IPSS score >19) 4, 2

When to Offer Treatment

Offer testosterone therapy when:

• Two morning total testosterone levels <300 ng/dL AND
• Presence of symptoms (especially sexual dysfunction, osteoporosis, or unexplained anemia) AND
• No contraindications present 1, 2, 1

For age-related low testosterone specifically: The 2018 Endocrine Society guideline 2 and 2020 American College of Physicians guideline 5 diverge somewhat. The Endocrine Society supports individualized treatment for symptomatic older men, while ACP recommends treatment primarily for sexual dysfunction with reassessment at 12 months. Given the priority on quality of life, offer treatment for sexual dysfunction but be more cautious about treating solely for energy/vitality, as evidence for these outcomes is weaker. 5, 6

Treatment Implementation

Target Testosterone Levels

• Aim for mid-normal range: 450-600 ng/dL during treatment 2, 7
• For injectable testosterone (enanthate/cypionate): measure mid-cycle levels, target 400-700 ng/dL 8, 2

Formulation Selection

Recommend intramuscular testosterone over transdermal formulations for initial therapy—clinical effectiveness and safety are equivalent, but intramuscular preparations cost significantly less 5. Options include:

• Testosterone enanthate or cypionate: 50-100 mg IM weekly or 100-200 mg every 2 weeks 8
• Transdermal gel (1%): 5-10 g daily if patient prefers (warn about transfer risk to others) 2
• Testosterone undecanoate (long-acting): measure trough levels before next injection 2

Mandatory Monitoring Protocol

Initial Follow-up (3-6 months)

• Assess symptom response (particularly sexual function if that was the indication)
• Measure testosterone level: adjust dose to achieve mid-normal range
• Check hematocrit: stop therapy if >54%, evaluate for hypoxia/sleep apnea, restart at lower dose when safe 2
• PSA and digital rectal exam (for men 55-69 years or 40-69 years at increased prostate cancer risk) 2

Annual Monitoring

• Symptom assessment and adverse effects
• Testosterone level
• Hematocrit
• PSA and digital rectal exam (age-appropriate)
• Bone mineral density after 1-2 years if osteoporosis was present 2

Triggers for Urological Referral

Refer immediately if:

• PSA increase >1.4 ng/mL within 12 months
• Confirmed PSA >4.0 ng/mL
• Abnormal digital rectal exam
• Substantial worsening of urinary symptoms 2, 4

When to Stop Treatment

Discontinue testosterone if:

• No symptom improvement after 12 months (especially for sexual dysfunction) 5
• Hematocrit >54% that doesn't resolve with dose reduction 2
• Development of contraindications (prostate abnormality, cardiovascular event)
• Patient preference after informed discussion

Key Clinical Pitfalls

1. Don't treat based on a single testosterone measurement—requires two separate early morning values 1
2. Don't treat asymptomatic men with low testosterone—diagnosis requires both low levels AND symptoms 1, 2
3. Don't skip prostate monitoring in men ≥55 years—testosterone increases PSA and may unmask subclinical prostate cancer 2
4. Don't ignore hematocrit elevation—this is the most common adverse effect requiring dose adjustment 2
5. Don't continue indefinitely without reassessing benefit—particularly for non-sexual symptoms where evidence is weaker 5

The most recent high-quality evidence (2018 Endocrine Society guideline 2 and 2020 ACP guideline 5, 6) supports a measured approach: treat symptomatic men with confirmed low testosterone, prioritize sexual dysfunction as the clearest indication, monitor carefully for hematologic and prostate effects, and reassess benefit within one year.